Gamco Investors INC. ET AL lowered its position in shares of Mylan (NASDAQ:MYL) by 55.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 6,500 shares of the company’s stock after selling 8,000 shares during the quarter. Gamco Investors INC. ET AL’s holdings in Mylan were worth $275,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Meeder Asset Management Inc. lifted its holdings in shares of Mylan by 76.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after buying an additional 1,475 shares during the period. BT Investment Management Ltd acquired a new position in shares of Mylan in the 3rd quarter valued at about $142,000. First Personal Financial Services lifted its holdings in shares of Mylan by 77.1% in the 4th quarter. First Personal Financial Services now owns 4,839 shares of the company’s stock valued at $205,000 after buying an additional 2,106 shares during the period. Mycio Wealth Partners LLC acquired a new position in shares of Mylan in the 4th quarter valued at about $212,000. Finally, Advisor Partners LLC acquired a new position in shares of Mylan in the 4th quarter valued at about $214,000. 75.56% of the stock is owned by institutional investors.
In other Mylan news, CEO Heather M. Bresch sold 75,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total transaction of $3,375,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.69% of the stock is currently owned by insiders.
Several equities analysts recently weighed in on the company. BidaskClub lowered Mylan from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 26th. Susquehanna Bancshares restated a “positive” rating and issued a $55.00 price target (up previously from $47.00) on shares of Mylan in a research note on Thursday, January 25th. Zacks Investment Research upgraded Mylan from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. Guggenheim assumed coverage on Mylan in a research note on Tuesday, December 12th. They issued a “buy” rating and a $59.00 price target for the company. Finally, Wells Fargo & Co set a $43.00 price target on Mylan and gave the company a “hold” rating in a research note on Thursday, January 18th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the company’s stock. Mylan has a consensus rating of “Buy” and a consensus price target of $44.65.
WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2018/02/14/gamco-investors-inc-et-al-lowers-holdings-in-mylan-myl.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.